ArticleProtein & cell2019
Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun.
Article in Protein & cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Advances in high-throughput drug screening based on pharmacotranscriptomics.Journal of advanced research · 2026Review
- IL-6 exacerbates calcium oxalate kidney stones by promoting inflammatory responses and crystal adhesion via p38 MAPK signaling activation.Urolithiasis · 2026Article
- High-throughput profiling of chemical-induced gene expression across 93,644 perturbations.Nature methods · 2025Article
- Large-Scale Transcriptome Profiling and Network Pharmacology Analysis Reveal the Multi-Target Inhibitory Mechanism of Modified Guizhi Fuling Decoction in Prostate Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Network toxicology and molecular docking reveal the potential link between acrylamide exposure and breast cancer.Scientific reports · 2025Article
- Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update.International journal of molecular sciences · 2025Review
- A tumor immune microenvironment gene expression signature for predicting prognosis, immunotherapy efficacy, and drug candidates in triple-negative breast cancer.Frontiers in immunology · 2025Article
- Gene Signature-Based Drug Screening Reveals Ponatinib Enhances Immunotherapy Efficacy in Triple-Negative Breast Cancer by Reversing MDSC-Mediated Immunosuppressive Tumor Microenvironment.Research (Washington, D.C.) · 2025Article
- lncRNA HIF1A-AS2 acts as an oncogene to regulate malignant phenotypes in cervical cancer.Frontiers in oncology · 2025Article
- Pulsatilla chinensis functions as a novel antihyperlipidemic agent by upregulating LDLR in an ERK-dependent manner.Chinese medicine · 2024Article
- Predictive model of gene expression regulating invasion and migration of M2 macrophages in breast cancer: clinical prognosis and therapeutic implications.Translational cancer research · 2024Article
- Erianin promotes endogenous neurogenesis in traumatic brain injury rats.Scientific reports · 2024Article
- Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis.Frontiers in pharmacology · 2024Article
- Wenshenyang recipe treats infertility through hormonal regulation and inflammatory responses revealed by transcriptome analysis and network pharmacology.Frontiers in pharmacology · 2022Article
- Taohong Siwu Decoction exerts anticancer effects on breast cancer via regulatingComputational and structural biotechnology journal · 2022Article
- FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional Chinese medicines.Science bulletin · 2021Article
- High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming.Frontiers in oncology · 2021Review
- Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds.Science advances · 2021Article
- Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.International journal of cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the leading cause of human cancer deaths. Unfortunately, no approved drugs are available for anti-metastatic treatment. In our study, high-throughput sequencing-based high-throughput screening (HTS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.